Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 15

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
comprised of the following:

    Schedule of share-based compensation expense 

    For the Six Months Ended June 30, 

    2025  
    2024 
  
    Research and development 
    $–  
    $4,867 
  
    General and administrative 
     –  
     – 
  
    Total 
    $–  
    $4,867 

The following summarizes our transaction activity
related to RSUs for the six months ended June 30, 2025:

    Schedule of RSU activity 

     Shares  
    Weighted Average Grant Date Fair Value 
  
    Nonvested and outstanding at January 1, 2025 
     510,513  
    $3.00 
  
    Granted 
     –  
     – 
  
    Vested 
     –  
     – 
  
    Forfeited 
     –  
     – 
  
    Nonvested and outstanding at June 30, 2025 
     510,513  
    $3.00 

As of June 30, 2025, there was no unrecognized compensation
cost related to RSUs. As of June 30, 2025, 14,044 RSUs have vested under the 2020 Plan since its adoption.

     13 

    9.
    Commitments and Contingencies

Legal Matters 

While the Company is not involved in any litigation
as of June 30, 2025, the Company may be involved in various lawsuits and claims arising in the ordinary course of business, including
actions with respect to intellectual property, employment, and contractual matters. Any litigation could have a material adverse effect
on the Company’s business, financial condition, results of operations, and/or cash flows in the period in which the unfavorable
outcome occurs or becomes probable, and potentially in future periods.

Indemnification

We have made certain guarantees and indemnities, under
which we may be required to make payments to a guaranteed or indemnified party. We indemnify our directors, officers, employees, and agents
to the maximum extent permitted under the laws of the State of Delaware. The duration of the guarantees and indemnities varies, and in
many cases is indefinite. These guarantees and indemnities do not provide for any limitation of the maximum potential future payments
we could be obligated to make. Historically, we have not been